Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

15 trials with published results (20%)

Research Maturity

51 completed trials (69% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.8%

5 terminated out of 74 trials

Success Rate

91.1%

+4.5% vs benchmark

Late-Stage Pipeline

14%

10 trials in Phase 3/4

Results Transparency

29%

15 of 51 completed with results

Key Signals

15 with results91% success

Data Visualizations

Phase Distribution

57Total
Not Applicable (20)
P 1 (16)
P 2 (11)
P 3 (9)
P 4 (1)

Trial Status

Completed51
Unknown7
Active Not Recruiting5
Terminated5
Not Yet Recruiting5
Recruiting1

Trial Success Rate

91.1%

Benchmark: 86.5%

Based on 51 completed trials

Clinical Trials (74)

Showing 20 of 20 trials
NCT07128615Phase 1Active Not RecruitingPrimary

A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

NCT05268939Completed

Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 Assessment

NCT05728970Completed

POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.

NCT05787444Completed

Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test

NCT07430410Not ApplicableNot Yet Recruiting

Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test

NCT05202379Phase 1CompletedPrimary

CC-42344 Safety Study in Healthy Participants

NCT06567860Phase 4CompletedPrimary

Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations

NCT07330986Completed

Influenza A-associated Pulmonary Aspergillosis in Patients Admitted to the Intensive Care Unit in China

NCT07308158CompletedPrimary

Covid Flu A/B and RSV 4 in 1 Diagnostic Test

NCT07190131Completed

Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test

NCT07314905Phase 3Not Yet RecruitingPrimary

Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)

NCT07229820Phase 3Active Not RecruitingPrimary

Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A

NCT07229807Phase 3Active Not RecruitingPrimary

Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A

NCT06656026Phase 2CompletedPrimary

Pharmacokinetics,Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza A

NCT07217639Not ApplicableNot Yet Recruiting

Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings

NCT06160531Phase 2CompletedPrimary

Influenza Viral Challenge Study of CC-42344 in Healthy Participants

NCT06008457Completed

Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit

NCT06734741Completed

Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use

NCT04896853Phase 1Active Not Recruiting

Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

NCT06191393Not ApplicableCompleted

SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings

Scroll to load more

Research Network

Activity Timeline